On 11 September 2026, TIGERMED (03347.HK) announced that its actual controllers Ye Xiaoping and Cao Xiaochun received on the same day a warning letter and a Prior Notice of Administrative Penalty (Zhe Zheng Fa Zi [2026] No. 21) issued by the Zhejiang Regional Office of the CSRC, and that the two are proposed to be given a warning and fined RMB 1 million in aggregate for suspected violations in information disclosure relating to changes in shareholding.
On 11 September 2026, SINO-OCEAN GP (03377.HK) provided an inside information update on the failure of its wholly-owned subsidiary Beijing Sino-Ocean Holdings Group to repay matured debts and on its litigation: as at 31 August 2026, its matured and unpaid borrowings totalled RMB 16.694 billion (compared with RMB 18.160 billion at the end of 2025), increasing by RMB 294 million during August, with no new major litigation in August 2026 and one case remaining as a dishonest judgment debtor.
On 11 September 2026, LIVZON PHARMA (01513.HK) announced that Mr. Zhu Baoguo resigned as chairman, a non-executive director, chairman of the strategy committee, chairman of the environmental, social and governance committee and the Company's legal representative on retirement, ceasing to hold any position in the Group while remaining the Company's actual controller; on the nomination committee's recommendation, President Mr. Liu Daping has been appointed as chairman and chairman of both committees for a term ending on the expiry of the twelfth session of the Board.
On 11 September 2026, HENGRUI PHARMA (01276.HK) announced that Ruzaltatug Rezetecan for Injection (SHR-A2009 for Injection) of its subsidiary Suzhou Suncadia Biopharmaceuticals Co., Ltd. has been included in the breakthrough therapy designation list by the Center for Drug Evaluation of the National Medical Products Administration, for use in combination with bevacizumab in patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC who have failed prior EGFR TKI treatment.
On 11 September 2026, SUNEVISION (01686.HK) announced that the wholly-owned subsidiary of its controlling shareholder, Sun Hung Kai Properties, has exercised its rights to convert all of its convertible notes in an aggregate amount of HKD 171,942,750.00 into 1,719,427,500 new shares, with the conversion date set at 27 October 2026, and that the public float of the Company will decrease to approximately 15.1029%.
On 11 September 2026, CHINA OVERSEAS (00688.HK) announced that the Stock Exchange has confirmed that the Company may proceed with the proposed spin-off on the Shenzhen Stock Exchange under Practice Note 15, and has granted the Company a waiver from strict compliance with paragraph 3(f) of Practice Note 15 regarding the requirement to provide an assured entitlement to shareholders.
On 11 September 2026, TECHTRONIC IND (00669.HK) announced that the board lot size of its shares for trading on the Main Board of the Stock Exchange will be changed from 500 shares to 100 shares with effect from 9:00 a.m. on 5 October 2026, reducing the market value of each board lot from HKD 63,500 to HKD 12,700 based on the closing price of HKD 127.00 per share on the date of the announcement.
On 11 September 2026, SHENGLONG INTL (08481.HK) published an inside information announcement on the receipt of land resumption compensation, under which the People's Government of Lin'an District, Hangzhou required its indirect wholly-owned subsidiary Zhejiang Shenglong to relocate its decorative paper manufacturing plant at No. 55, Shangyang Road, with total compensation of approximately RMB 364 million, of which approximately RMB 181 million has been received.
On 11 September 2026, PKU RESOURCES (00618.HK) announced that executive director Mr. Hou Ruilin resigned with effect from 11 September 2026 to devote more time to his personal affairs, and that Ms. Xiong Yan was appointed as an executive director on the same date at an annual director's remuneration of HKD 1.00.
On 11 September 2026, FUJING HOLDINGS (02497.HK) announced that executive director and Financial Controller Mr. Lyu Zhonghua decided to resign with effect from 10 September 2026 after considering his other personal work arrangements, and the Company is identifying a suitable candidate to fill the vacancy in the position of Financial Controller.
The China Securities Regulatory Commission (CSRC) has recently issued a notice on the filing of the overseas offering and listing and the "Full Circulation" of unlisted domestic shares of AMICRO SEMICONDUCTOR CO., LTD. (Zhuhai Amicro Technology Co., Ltd.), confirming that the company intends to issue not more than 90,911,400 overseas-listed ordinary shares and to have them listed on The Stock Exchange of Hong Kong Limited, and that 43 shareholders intend to convert an aggregate of 360,133,644 unlisted domestic shares held by them into overseas-listed shares and to have them listed and traded on the Stock Exchange.
On 11 September 2026, SEAZEN (01030.HK) announced unaudited operating data for August 2026, with 183 investment properties totalling approximately 16.9092 million sqm and monthly rental income of approximately RMB 1.206 billion and commercial operation revenue of approximately RMB 1.291 billion; for January to August 2026, cumulative rental income was approximately RMB 9.000 billion and cumulative commercial operation revenue approximately RMB 9.644 billion, while August contracted sales were approximately RMB 889 million over approximately 140,900 sqm and cumulative contracted sales reached approximately RMB 8.107 billion over approximately 1,305,400 sqm.
On 11 September 2026, FOSUN PHARMA (02196.HK) announced that the NMPA has accepted the drug registration application for the 120mg (1.7ml) vial specification of HLX14, a recombinant anti-RANKL fully human monoclonal antibody injection developed by its subsidiary Henlius as a denosumab biosimilar, covering all indications of the reference product Xgeva approved in mainland China; HLX14 (60mg/mL and 120mg/1.7mL) is already approved in the US, EU, UK and Canada, the group's cumulative R&D investment reached approximately RMB 352 million as at August 2026, and global denosumab sales were approximately USD 8.092 billion in 2025.
On 11 September 2026, SHUI ON LAND (00272.HK) announced the sale of the commercial property at Levels 1 to 6, No. 6 Ruitian Road, Yuzhong District, Chongqing, with a total GFA of 31,286.56 sqm, to Chongqing Shengjugé Real Estate Brokerage for approximately RMB 201,000,000 (approximately HKD 232,682,000) with a RMB 35,000,000 deposit; the property had a carrying amount of approximately RMB 190,000,000 as at 30 June 2026, no material gain or loss is expected, net cash inflow of approximately RMB 179,000,000 will be used for general working capital and annual revenue will fall by approximately RMB 14,000,000, with the disposal constituting a discloseable transaction exempt from circular and shareholders' approval.
On 11 September 2026, SHENZHEN INT'L (00152.HK) announced the completion of its 2026 fourth tranche of medium-term notes, comprising RMB 1 billion with a coupon rate of 2.07% and a 10-year term; the company had obtained approval to register multi-variety debt financing instruments of up to RMB 10 billion and has previously issued its 2024 first tranche (RMB 4 billion) and 2026 first to third tranches (RMB 1 billion, RMB 2 billion and RMB 1 billion), with issuance documents published on ChinaMoney and the Shanghai Clearing House website.
On 11 September 2026, SHIMAO GROUP (00813.HK) announced unaudited operating data for the eight months ended 31 August 2026, with cumulative contracted sales of approximately RMB 9.721 billion, cumulative contracted sales area of 792,172 sqm and an average selling price of RMB 12,271 per sqm, while August 2026 contracted sales were approximately RMB 710 million over 58,969 sqm at an average price of RMB 12,045 per sqm; the company noted the data is unaudited and may differ from figures in its audited financial statements, and is for reference only.
